Tech Company Financing Transactions
Delix Therapeutics Funding Round
Delix Therapeutics closed a $100 million Series C funding round on 11/9/2026. Investors included Johnson & Johnson Development Corporation, SV Health Investors and Adage Capital Management.
Transaction Overview
Company Name
Announced On
11/9/2026
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to advance Zalsupindole through Phase IIb Proof of Concept in recurrent Major Depressive Disorder while supporting the continued development and expansion of its broader neuroplastogen pipeline into clinical stages, including its neurodegeneration program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA 02139
USA
Boston, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, we are building a world class CNS company on a mission to broaden patient access to safe, fast-acting, and long-lasting medicines for many of the leading causes of disability worldwide.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/9/2026: Shield AI venture capital transaction
Next: 11/9/2026: Onodrim Industries venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








